Last reviewed · How we verify
Crisaborole 2% Top Oint
At a glance
| Generic name | Crisaborole 2% Top Oint |
|---|---|
| Sponsor | Massachusetts General Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparative Evaluation of the Safety and Effectiveness of Crisaborole Ointment (2%) Versus Tacrolimus Ointment (0.1%) for the Topical Treatment of Atopic Dermatitis (PHASE4)
- Microneedling Combined With Topical Crisaborole 2 % Ointment in Treatment of Vitiligo. (NA)
- Skin bioMARkers for Atopic Eczema Therapy Evaluation (PHASE2)
- Eucrisa for Atopic Dermatitis (PHASE1)
- Topical Crisaborole in Patients with Alopecia Areata (PHASE2)
- Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo (PHASE2)
- Characterizing Skin Microbiome Change in Atopic Dermatitis (EARLY_PHASE1)
- Response of Children With Atopic Dermatitis (Eczema) to Eucrisa (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Crisaborole 2% Top Oint CI brief — competitive landscape report
- Crisaborole 2% Top Oint updates RSS · CI watch RSS
- Massachusetts General Hospital portfolio CI